BCL2L1-AS1

Across TCGA pan-cancer cohorts, BCL2L1-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of BCL2L1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where BCL2L1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCL2L1-AS1 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

STAD, KIRC, and HNSC are the cancer types where BCL2L1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.848	<.001	9	view →
KIRC	Male	All	+0.270	<.001	9	view →
HNSC	All	II,III,IV	+0.196	.001	8	view →
COAD	All	All	+0.323	.004	6	view →
CHOL	All	All	+0.498	.003	3	view →
LUSC	Female	All	−0.567	.007	2	view →
LUAD	All	IV	−0.295	.010	2	view →
BRCA	All	All	+0.288	.022	2	view →
BLCA	Female	IV	+0.363	.040	1	view →
LIHC	All	II,III,IV	+0.072	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

BCL2L1-AS1–STAD

Open the STAD breakdown →